1. Efficacy analysis of unrelated cord blood transplantation in the treatment of refractory and relapsed adult acute leukemia
Xiandeng CHU ; Erling CHEN ; Xiaoyu ZHU ; Baolin TANG ; Changcheng ZHENG ; Kaidi SONG ; Xuhan ZHANG ; Juan TONG ; Xiang WAN ; Lei ZHANG ; Huilan LIU ; Zimin SUN
Chinese Journal of Hematology 2018;39(2):105-109
Objective:
To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of refractory and relapsed acute leukemia (AL) patients.
Methods:
The clinical data of 22 refractory and relapsed AL patients who were treated with UCBT as salvage therapy from November 2009 to May 2017 were retrospectively analyzed. All patients received a myeloablative conditioning regimen for prevention of graft-versus-host disease (GVHD) with cyclosporine A (CSA)/short course of mycophenolate mofetil (MMF).
Results:
①Of 22 patients, 9 cases were male and 13 female. The median age was 23 (15-44) years and median weight of 52.5 (43-82) kg. All patients were transplanted with a median umbilical cord blood nucleated cells of 3.07 (1.71-5.30)×107/kg (by weight), the median CD34+ cells was 1.60 (0.63-3.04)×105/kg (by weight). ②The myeloid cumulative implantation rate was 95.5% (95%